New device aims to make cancer biopsies more precise

NCT ID NCT06199492

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a new imaging device called tVisio-1 that helps doctors see tumor tissue before taking a biopsy sample. The goal is to make biopsies more accurate and reduce complications. About 150 adults with suspected or confirmed cancer will participate at MD Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tVisio-1 imaging device
What this could lead to: If successful, this device could make biopsies more accurate by helping doctors target tumor tissue directly, potentially reducing the need for repeat procedures.
What could go wrong: This is an early-stage feasibility study with only 150 participants, so the device may not prove more effective than standard methods. There is also a risk of device-related adverse events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEEDLE BIOPSY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.